NASDAQ:INVO - INVO Bioscience Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.25
  • Forecasted Upside: 40.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.75
▼ -0.18 (-4.58%)

This chart shows the closing price for INVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New INVO Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVO

Analyst Price Target is $5.25
▲ +40.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for INVO Bioscience in the last 3 months. The average price target is $5.25, with a high forecast of $5.25 and a low forecast of $5.25. The average price target represents a 40.00% upside from the last price of $3.75.

This chart shows the closing price for INVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in INVO Bioscience.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2021Roth CapitalLower Price TargetBuy$5.75 ➝ $5.25Medium
12/29/2020Roth CapitalReiterated RatingBuyN/A
12/29/2020Roth CapitalInitiated CoverageBuyN/A
12/15/2020Colliers SecuritiesReiterated RatingBuyHigh
12/15/2020Colliers SecuritiesInitiated CoverageBuyMedium
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/25/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
INVO Bioscience logo
INVO BioScience, Inc. focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.
Read More

Today's Range

Now: $3.75
Low: $3.64
High: $3.89

50 Day Range

MA: $3.71
Low: $3.17
High: $4.25

52 Week Range

Now: $3.75
Low: $2.90
High: $12.30

Volume

56,490 shs

Average Volume

645,830 shs

Market Capitalization

$39.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of INVO Bioscience?

The following sell-side analysts have issued research reports on INVO Bioscience in the last twelve months: Colliers Securities, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for INVO.

What is the current price target for INVO Bioscience?

1 Wall Street analysts have set twelve-month price targets for INVO Bioscience in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 40.0%. Roth Capital has the highest price target set, predicting INVO will reach $5.25 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $5.25 for INVO Bioscience in the next year.
View the latest price targets for INVO.

What is the current consensus analyst rating for INVO Bioscience?

INVO Bioscience currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INVO will outperform the market and that investors should add to their positions of INVO Bioscience.
View the latest ratings for INVO.

What other companies compete with INVO Bioscience?

How do I contact INVO Bioscience's investor relations team?

INVO Bioscience's physical mailing address is 5582 BROADCAST COURT, SARASOTA FL, 34240. The company's listed phone number is (978) 878-9505 and its investor relations email address is [email protected] The official website for INVO Bioscience is www.invobioscience.com.